<DOC>
	<DOC>NCT01312766</DOC>
	<brief_summary>The purpose of the non-inferiority study is to evaluate the clinical efficacy and the safety of two different subcutaneous hMG preparations when administered to patients undergoing controlled ovarian stimulation for IVF.</brief_summary>
	<brief_title>Safety and Efficacy Study in in Vitro Fertilisation (IVF) Patients</brief_title>
	<detailed_description />
	<mesh_term>Infertility</mesh_term>
	<criteria>Women undergoing ovarian stimulation for IVF with the following characteristics: Able and willing to sign the Patient Consent Form and adhere to the study visitation schedule &gt;18 and &lt;40 years old BMI between 18 and 30 kg/m2 less than 3 previously completed IVF cycles (i.e. completed cycle = egg recovery) basal FSH &lt;10 IU/L and E2 &lt;80 pg/ml (~290 pmol/l) Within 12 months of the beginning of the study, uterine cavity consistent with expected normal function as assessed through transvaginal ultrasound, hysterosalpingogram, sonohysterogram or hysteroscopic examination Successful downregulation performed with a standard GnRHAgonist long protocol (Criteria for successful downregulation: endometrial thickness &lt; 7mm or serum E2 level &lt;50 pg/ml (~185 pmol/l). age &lt;18 and &gt;40 years primary ovarian failure or women known as poor responders (i.e. requiring more than 225 IU of hMG as a starting dose in previous treatment cycles or having less than 3 oocytes retrieved, or with a preovulatory E2 serum concentration &lt;500pg/ml (~1800 pmol/l)) PCOS one or both ovaries inaccessible for oocyte retrieval ovarian cysts &gt;10 mm hydrosalpinx that have not been surgically removed or ligated; stage 3 or 4 endometriosis oocyte donation implantation of previously frozen embryos patients affected by pathologies associated with any contraindication of being pregnant hypersensitivity to the study medication abnormal bleeding of undetermined origin uncontrolled thyroid or adrenal dysfunction neoplasias severe impairment of renal and/or hepatic function use of concomitant medications that might interfere with study evaluations (e.g. nonstudy hormonal medications, prostaglandin inhibitors, psychotropic agents)</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>